Information on EC 5.2.1.8 - Peptidylprolyl isomerase

New: Word Map on EC 5.2.1.8
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Mark a special word or phrase in this record:
Search Reference ID:
Select one or more organisms in this record:
Show additional data
Do not include text mining results
Include (text mining) results (more...)
Include results (AMENDA + additional results, but less precise; more...)

The enzyme appears in viruses and cellular organisms

EC NUMBER
COMMENTARY hide
5.2.1.8
-
RECOMMENDED NAME
GeneOntology No.
Peptidylprolyl isomerase
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
peptidylproline (omega=180) = peptidylproline (omega=0)
show the reaction diagram
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
cis-trans-isomerization
rotation
-
-
single bond
-
SYSTEMATIC NAME
IUBMB Comments
Peptidylproline cis-trans-isomerase
The first type of this enzyme found [1] proved to be the protein cyclophilin, which binds the immunosuppressant cyclosporin A. Other distinct families of the enzyme exist, one being FK-506 binding proteins (FKBP) and another that includes parvulin from Escherichia coli. The three families are structurally unrelated and can be distinguished by being inhibited by cyclosporin A, FK-506 and 5-hydroxy-1,4-naphthoquinone, respectively.
CAS REGISTRY NUMBER
COMMENTARY hide
95076-93-0
-
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
-
-
-
Manually annotated by BRENDA team
gene PPIB
UniProt
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
strain 81-176, gene cj0596
-
-
Manually annotated by BRENDA team
strain 81-176, gene cj0596
-
-
Manually annotated by BRENDA team
cyclophilin A
UniProt
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
UniProt
Manually annotated by BRENDA team
-
UniProt
Manually annotated by BRENDA team
-
Swissprot
Manually annotated by BRENDA team
-
UniProt
Manually annotated by BRENDA team
-
UniProt
Manually annotated by BRENDA team
soluble expression in Escherichia coli
SwissProt
Manually annotated by BRENDA team
soluble expression in Escherichia coli
SwissProt
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
SwissProt
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
UniProt
Manually annotated by BRENDA team
isoform RcCyp1
UniProt
Manually annotated by BRENDA team
GenBank
SwissProt
Manually annotated by BRENDA team
strains C5 and SL1344, genes surA and fkpA. SurA can functionally compensate for the absence of FkpA, but when SurA is missing, or especially when both SurA and FkpA are missing, the ability of cells to survive or recover from prolonged periods of C-starvation is significantly impaired
-
-
Manually annotated by BRENDA team
cv. VF36
-
-
Manually annotated by BRENDA team
study on enzyme activity in drought tolerant and drought susceptible cultivars. In drought tolerant cultivars, significant water stress increases leaf enzyme activity, whereas in drought-susceptible cultivar enzyme activity decreases in response to drought
-
-
Manually annotated by BRENDA team
-
Uniprot
Manually annotated by BRENDA team
KS-1
-
-
Manually annotated by BRENDA team
cv Atir
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
evolution
malfunction
physiological function
additional information
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
(trans)-Pro190 of protein phosphatase 2A
(cis)-Pro190 of protein phosphatase 2A
show the reaction diagram
4-aminobenzoyl-Cys-Lys-(trans)-Pro-Ala-Cys-(NO2)-Tyr-NH2
4-aminobenzoyl-Cys-Lys-(cis)-Pro-Ala-Cys-(NO2)-Tyr-NH2
show the reaction diagram
4-aminobenzoyl-Cys-Lys-(trans)-Pro-Gly-Cys-(NO2)-Tyr-NH2
4-aminobenzoyl-Cys-Lys-(cis)-Pro-Gly-Cys-(NO2)-Tyr-NH2
show the reaction diagram
4-aminobenzoyl-Cys-Phe-(trans)-Pro-Val-Cys-(NO2)-Tyr-NH2
4-aminobenzoyl-Cys-Phe-(cis)-Pro-Val-Cys-(NO2)-Tyr-NH2
show the reaction diagram
acetyl-Ala-Ala-(cis)-Pro-Ala-Lys-NH2
acetyl-Ala-Ala-(trans)-Pro-Ala-Lys-NH2
show the reaction diagram
-
-
-
?
acetyl-Ala-Ala-Ser(PO3H2)-(cis)-Pro-Arg-NH-4-nitroanilide
acetyl-Ala-Ala-Ser(PO3H2)-(trans)-Pro-Arg-NH-4-nitroanilide
show the reaction diagram
AGL24 protein
?
show the reaction diagram
Ala-Ala-(cis)-Pro-Ala
Ala-Ala-(trans)-Pro-Ala
show the reaction diagram
-
-
-
?
Ala-Ala-(trans)-Pro-Phe
Ala-Ala-(cis)-Pro-Phe
show the reaction diagram
-
-
-
r
Ala-Ala-Ala-(trans)-Pro-Phe
Ala-Ala-Ala-(cis)-Pro-Phe
show the reaction diagram
-
-
-
r
Ala-Gln-(cis)-Pro-Phe
Ala-Gln-(trans)-Pro-Phe
show the reaction diagram
Ala-Glu-(cis)-Pro-Phe
Ala-Glu-(trans)-Pro-Phe
show the reaction diagram
Ala-Glu-(cis)-Pro-Phe-4-nitroanilide
Ala-Glu-(trans)-Pro-Phe-4-nitroanilide
show the reaction diagram
-
-
-
-
?
Ala-Ile-(cis)-Pro-Phe
Ala-Ile-(trans)-Pro-Phe
show the reaction diagram
Ala-Leu-(cis)-Pro-Phe
Ala-Leu-(trans)-Pro-Phe
show the reaction diagram
Ala-Nle-(cis)-Pro-Phe
Ala-Nle-(trans)-Pro-Phe
show the reaction diagram
Ala-Ser(PO3H2)-(cis)-Pro
Ala-Ser(PO3H2)-(trans)-Pro
show the reaction diagram
-
-
-
?
Ala-Ser(PO3H2)-(cis)-Pro-Arg
Ala-Ser(PO3H2)-(trans)-Pro-Arg
show the reaction diagram
-
-
-
?
Ala-Val-(cis)-Pro-Phe
Ala-Val-(trans)-Pro-Phe
show the reaction diagram
-
-
?
amyloidbeta precursor protein
?
show the reaction diagram
-
interaction with Thr688
-
-
?
barstar C40A/C82A/P27A
?
show the reaction diagram
-
the mutant of barstar lacks complications arising from oxidation of Cys in wild-type or isomerization affecting the peptidyl-Pro27 bond. Refolding is comprised by several kinetically detectable folding phases. The slowest phase in refolding, the trans to cis isomerization of the Tyr47-Pro48 peptide bond being in cis conformation in the native state
-
?
cis-succinyl-Ala-Leu-Pro-Phe-p-nitroanilide
trans-succinyl-Ala-Leu-Pro-Phe-p-nitroanilide
show the reaction diagram
-
-
-
?
colicin M
?
show the reaction diagram
D-Glyceraldehyde 3-phosphate
Glycerone phosphate
show the reaction diagram
-
-
-
-
GFPRALPAWARPDYNPPLVE
?
show the reaction diagram
-
a synthetic peptide, named PepD2, corresponding to residues 304-323 of NS5A
-
-
?
Glutaryl-Ala-Ala-(cis)-Pro-Phe 4-nitroanilide
Glutaryl-Ala-Ala-(trans)-Pro-Phe 4-nitroanilide
show the reaction diagram
Glutaryl-Ala-Ala-Ala-(cis)-Pro-Phe 4-nitroanilide
Glutaryl-Ala-Ala-Ala-(trans)-Pro-Phe 4-nitroanilide
show the reaction diagram
-
-
-
-
Glutaryl-Ala-Gly-(cis)-Pro-Phe 4-nitroanilide
Glutaryl-Ala-Gly-(trans)-Pro-Phe 4-nitroanilide
show the reaction diagram
-
-
-
-
Glutaryl-Ala-Pro-(cis)-Phe 4-nitroanilide
Glutaryl-Ala-Pro-(trans)-Phe 4-nitroanilide
show the reaction diagram
-
-
-
-
hepatitis C virus NS5A protein
?
show the reaction diagram
interleukin-2 tyrosine kinase
?
show the reaction diagram
-
catalytic activity of interleukin-2 tyrosine kinase is inhibited by peptidylprolyl isomerase activity of cyclophilin A. Proline-dependent conformational switch within the interleukin-2 tyrosine kinase SH2 domain regulates substrate recognition and mediates regulatory interactions with the active site of cyclophilin A
-
?
N-succinyl-Ala-Ala-(cis)-Pro-Phe-4-nitroanilide
N-succinyl-Ala-Ala-(trans)-Pro-Phe-4-nitroanilide
show the reaction diagram
6.9% activity compared to N-succinyl-Ala-Arg-(cis)-Pro-Phe-4-nitroanilide
-
-
?
N-succinyl-Ala-Ala-(cis)-Pro-Phe-p-nitroanilide
N-succinyl-Ala-Ala-(trans)-Pro-Phe-p-nitroanilide
show the reaction diagram
N-succinyl-Ala-Ala-(trans)-Pro-Phe-4-nitroanilide
N-succinyl-Ala-Ala-(cis)-Pro-Phe-4-nitroanilide
show the reaction diagram
N-succinyl-Ala-Ala-Pro-Phe-4-nitroanilide
?
show the reaction diagram
N-succinyl-Ala-Arg-(cis)-Pro-Phe-4-nitroanilide
N-succinyl-Ala-Arg-(trans)-Pro-Phe-4-nitroanilide
show the reaction diagram
100% activity, Par45 shows a strong preference for a substrate with the basic Arg residue preceding Pro
-
-
?
N-succinyl-Ala-Glu-(cis)-Pro-Phe-4-nitroanilide
N-succinyl-Ala-Glu-(trans)-Pro-Phe-4-nitroanilide
show the reaction diagram
7.6% activity compared to N-succinyl-Ala-Arg-(cis)-Pro-Phe-4-nitroanilide
-
-
?
N-succinyl-Ala-Glu-(trans)-Pro-Phe-4-nitroanilide
N-succinyl-Ala-Glu-(cis)-Pro-Phe-4-nitroanilide
show the reaction diagram
N-succinyl-Ala-Leu-(cis)-Pro-Phe-4-nitroanilide
N-succinyl-Ala-Leu-(trans)-Pro-Phe-4-nitroanilide
show the reaction diagram
26.7% activity compared to N-succinyl-Ala-Arg-(cis)-Pro-Phe-4-nitroanilide
-
-
?
N-succinyl-Ala-Leu-(cis)-Pro-Phe-p-nitroanilide
N-succinyl-Ala-Leu-(trans)-Pro-Phe-p-nitroanilide
show the reaction diagram
N-succinyl-Ala-Leu-(trans)-Pro-Phe-4-nitroanilide
N-succinyl-Ala-Leu-(cis)-Pro-Phe-4-nitroanilide
show the reaction diagram
N-succinyl-Ala-Phe-(cis)-Pro-Phe-4-nitroanilide
N-succinyl-Ala-Phe-(trans)-Pro-Phe-4-nitroanilide
show the reaction diagram
4.3% activity compared to N-succinyl-Ala-Arg-(cis)-Pro-Phe-4-nitroanilide
-
-
?
N-succinyl-Ala-Phe-(trans)-Pro-Phe-4-nitroanilide
N-succinyl-Ala-Phe-(cis)-Pro-Phe-4-nitroanilide
show the reaction diagram
-
-
-
?
peptidylproline (omega=180)
peptidylproline (omega=0)
show the reaction diagram
Phe-Phe-L-pSer-Pro-Arg-pNA
?
show the reaction diagram
-
-
-
-
?
phosphorylated pro-apoptotic Bcl-2-associated X protein
?
show the reaction diagram
PP2A phosphatase with cis-P190
PP2A phosphatase with trans-P190
show the reaction diagram
protein tau
?
show the reaction diagram
-
interaction with Thr231 of tau in Alzheimer's disease
-
-
?
reduced carboxymethylated bovine alpha-lactalbumin
reduced carboxymethylated bovine alpha-lactalbumin
show the reaction diagram
-
-
-
-
?
RNA polymerase II
?
show the reaction diagram
RNase A S-protein
RNase A S-protein
show the reaction diagram
-
partially folded
action of enzyme greatly reduces the population of aggregated oligomeric species
-
?
RNAse T1
?
show the reaction diagram
Ser(PO3H2)-(cis)-Pro-Arg
Ser(PO3H2)-(trans)-Pro-Arg
show the reaction diagram
-
-
-
?
Ser(PO3H2)-(cis)-Pro-Arg-NH-4-nitroanilide
Ser(PO3H2)-(trans)-Pro-Arg-NH-4-nitroanilide
show the reaction diagram
-
-
-
?
serine/threonine protein kinase B
?
show the reaction diagram
SOC1 protein
?
show the reaction diagram
Suc-Ala-Ala-(trans)-Pro-Lys-p-nitroanilide
Suc-Ala-Ala-(cis)-Pro-Lys-p-nitroanilide
show the reaction diagram
Suc-Ala-Ala-(trans)-Pro-Phe-methylcoumarylamide
Suc-Ala-Ala-(cis)-Pro-Phe-methylcoumarylamide
show the reaction diagram
Suc-Ala-Ala-(trans)-Pro-Phe-p-nitroanilide
Suc-Ala-Ala-(cis)-Pro-Phe-p-nitroanilide
show the reaction diagram
Suc-Ala-Ala-cis-Pro-Phe-4-nitroanilide
Suc-Ala-Ala-trans-Pro-Phe-4-nitroanilide
show the reaction diagram
cis/trans-isomerization
-
-
?
suc-Ala-Glu-(cis)-Pro-Phe-4-nitroanilide
suc-Ala-Glu-(trans)-Pro-Phe-4-nitroanilide
show the reaction diagram
-
-
-
-
?
Suc-Ala-Glu-(trans)-Pro-Phe-p-nitroanilide
Suc-Ala-Glu-(cis)-Pro-Phe-p-nitroanilide
show the reaction diagram
Suc-Ala-Glu-Pro-Phe-4-nitroanilide
?
show the reaction diagram
-
-
-
-
?
Suc-Ala-Glu-Pro-Phe-7-amido-4-methylcoumarin
?
show the reaction diagram
Suc-Ala-Leu-cis-Pro-Phe-4-nitroanilide
Suc-Ala-Leu-trans-Pro-Phe-4-nitroanilide
show the reaction diagram
cis/trans-isomerization
-
-
?
succinyl-Ala-(cis)-Pro-Phe-NH-4-nitroanilide
succinyl-Ala-(trans)-Pro-Phe-NH-4-nitroanilide
show the reaction diagram
-
-
-
?
succinyl-Ala-Ala-(cis)-Pro-Lys-4-methylcoumarin-7-amide
succinyl-Ala-Ala-(trans)-Pro-Lys + 7-amino-4-methylcoumarin
show the reaction diagram
succinyl-Ala-Ala-(cis)-Pro-Phe 4-methylcoumarin 7-amide
succinyl-Ala-Ala-(trans)-Pro-Phe + 7-amino-4-methylcoumarin
show the reaction diagram
succinyl-Ala-Ala-(cis)-Pro-Phe-4-nitroanilide
succinyl-Ala-Ala-(trans)-Pro-Phe-4-nitroanilide
show the reaction diagram
succinyl-Ala-Ala-(cis)-Pro-Phe-NH-4-nitroanilide
succinyl-Ala-Ala-(trans)-Pro-Phe-NH-4-nitroanilide
show the reaction diagram
-
-
-
?
succinyl-Ala-Ala-(cis)-Pro-Phe-p-nitroanilide
succinyl-Ala-Ala-(trans)-Pro-Phe-p-nitroanilide
show the reaction diagram
succinyl-Ala-Ala-(trans)-Pro-Arg-p-nitroanilide
succinyl-Ala-Ala-(cis)-Pro-Arg-p-nitroanilide
show the reaction diagram
-
-
-
r
succinyl-Ala-Ala-(trans)-Pro-Phe-4-nitroanilide
succinyl-Ala-Ala-(cis)-Pro-Phe-4-nitroanilide
show the reaction diagram
succinyl-Ala-Ala-Pro-Phe 4-nitroanilide
succinyl-Ala-Ala-(trans)-Pro-Phe 4-nitroanilide
show the reaction diagram
succinyl-Ala-Arg-(cis)-Pro-Phe-4-nitroanilide
succinyl-Ala-Arg-(trans)-Pro-Phe-4-nitroanilide
show the reaction diagram
50% of activity compared to succinyl-Ala-Leu-(cis)-Pro-Phe-4-nitroanilide
-
-
?
Succinyl-Ala-Gln-(cis)-Pro-Phe 4-nitroanilide
Succinyl-Ala-Gln-(trans)-Pro-Phe 4-nitroanilide
show the reaction diagram
-
-
-
-
succinyl-Ala-Gln-(cis)-Pro-Phe-4-nitroanilide
succinyl-Ala-Gln-(trans)-Pro-Phe-4-nitroanilide
show the reaction diagram
65% of activity compared to succinyl-Ala-Leu-(cis)-Pro-Phe-4-nitroanilide
-
-
?
succinyl-Ala-Gln-(cis)-Pro-Phe-p-nitroanilide
succinyl-Ala-Gln-(trans)-Pro-Phe-p-nitroanilide
show the reaction diagram
-
27% of the activity with succinyl-Ala-Ala-(cis)-Pro-Phe-p-nitroanilide
-
-
?
Succinyl-Ala-Glu-(cis)-Pro-Phe 4-nitroanilide
Succinyl-Ala-Glu-(trans)-Pro-Phe 4-nitroanilide
show the reaction diagram
succinyl-Ala-Glu-(cis)-Pro-Phe-4-nitroanilide
succinyl-Ala-Glu-(trans)-Pro-Phe-4-nitroanilide
show the reaction diagram
succinyl-Ala-Glu-(cis)-Pro-Phe-p-nitroanilide
succinyl-Ala-Glu-(trans)-Pro-Phe-p-nitroanilide
show the reaction diagram
-
13% of the activity with succinyl-Ala-Ala-(cis)-Pro-Phe-p-nitroanilide
-
-
?
succinyl-Ala-Glu-(trans)-Pro-Phe-4-nitroanilide
succinyl-Ala-Glu-(cis)-Pro-Phe-4-nitroanilide
show the reaction diagram
succinyl-Ala-Glu-(trans)-Pro-Phe-7-amido-4-methylcoumarin
succinyl-Ala-Glu-(cis)-Pro-Phe-7-amido-4-methylcoumarin
show the reaction diagram
-
-
-
r
Succinyl-Ala-Gly-(cis)-Pro-Phe 4-nitroanilide
Succinyl-Ala-Gly-(trans)-Pro-Phe 4-nitroanilide
show the reaction diagram
succinyl-Ala-Gly-(cis)-Pro-Phe-4-nitroanilide
succinyl-Ala-Gly-(trans)-Pro-Phe-4-nitroanilide
show the reaction diagram
-
-
-
?
succinyl-Ala-Gly-(cis)-Pro-Phe-p-nitroanilide
succinyl-Ala-Gly-(trans)-Pro-Phe-p-nitroanilide
show the reaction diagram
-
37% of the activity with succinyl-Ala-Ala-(cis)-Pro-Phe-p-nitroanilide
-
-
?
Succinyl-Ala-His-(cis)-Pro-Phe 4-nitroanilide
Succinyl-Ala-His-(trans)-Pro-Phe 4-nitroanilide
show the reaction diagram
succinyl-Ala-His-(trans)-Pro-Phe-4-nitroanilide
succinyl-Ala-His-(cis)-Pro-Phe-4-nitroanilide
show the reaction diagram
-
-
-
r
Succinyl-Ala-Leu-(cis)-Pro-Phe 4-nitroanilide
Succinyl-Ala-Leu-(trans)-Pro-Phe 4-nitroanilide
show the reaction diagram
succinyl-Ala-Leu-(cis)-Pro-Phe-4-nitroanilide
succinyl-Ala-Leu-(trans)-Pro-Phe-4-nitroanilide
show the reaction diagram
-
-
-
?
succinyl-Ala-Leu-(cis)-Pro-Phe-p-nitroanilide
succinyl-Ala-Leu-(trans)-Pro-Phe-p-nitroanilide
show the reaction diagram
succinyl-Ala-Leu-(trans)-Pro-Phe-4-nitroanilide
succinyl-Ala-Leu-(cis)-Pro-Phe-4-nitroanilide
show the reaction diagram
-
-
-
r
succinyl-Ala-Leu-Pro(omega180)-Phe-4-nitroanilide
succinyl-Ala-Leu-Pro(omega0)-Phe-4-nitroanilide
show the reaction diagram
the substrate binds to PvFKBD35 in a cis conformation involving residues D55, H67, V73, and I74
-
-
?
Succinyl-Ala-Lys-(cis)-Pro-Phe 4-nitroanilide
Succinyl-Ala-Lys-(trans)-Pro-Phe 4-nitroanilide
show the reaction diagram
succinyl-Ala-Lys-(cis)-Pro-Phe-4-nitroanilide
succinyl-Ala-Lys-(trans)-Pro-Phe-4-nitroanilide
show the reaction diagram
83% of activity compared to succinyl-Ala-Leu-(cis)-Pro-Phe-4-nitroanilide
-
-
?
succinyl-Ala-Nle-(cis)-Pro-Phe-4-nitroanilide
succinyl-Ala-Nle-(trans)-Pro-Phe-4-nitroanilide
show the reaction diagram
194% of activity compared to succinyl-Ala-Leu-(cis)-Pro-Phe-4-nitroanilide
-
-
?
Succinyl-Ala-Phe-(cis)-Pro-Phe 4-nitroanilide
Succinyl-Ala-Phe-(trans)-Pro-Phe 4-nitroanilide
show the reaction diagram
succinyl-Ala-Phe-(cis)-Pro-Phe-4-nitroanilide
succinyl-Ala-Phe-(trans)-Pro-Phe-4-nitroanilide
show the reaction diagram
succinyl-Ala-Phe-(cis)-Pro-Phe-p-nitroanilide
succinyl-Ala-Phe-(trans)-Pro-Phe-p-nitroanilide
show the reaction diagram
succinyl-Ala-Phe-(trans)-Pro-Phe-4-nitroanilide
succinyl-Ala-Phe-(cis)-Pro-Phe-4-nitroanilide
show the reaction diagram
succinyl-Ala-Phe-Pro-Phe-4-nitroanilide
?
show the reaction diagram
-
-
-
-
?
succinyl-Ala-Ser-(cis)-Pro-Phe-4-nitroanilide
succinyl-Ala-Ser-(trans)-Pro-Phe-4-nitroanilide
show the reaction diagram
23% of activity compared to succinyl-Ala-Leu-(cis)-Pro-Phe-4-nitroanilide
-
-
?
Succinyl-Ala-Val-(cis)-Pro-Phe 4-nitroanilide
Succinyl-Ala-Val-(trans)-Pro-Phe 4-nitroanilide
show the reaction diagram
-
-
-
-
succinyl-Ala-Val-(cis)-Pro-Phe-4-nitroanilide
succinyl-Ala-Val-(trans)-Pro-Phe-4-nitroanilide
show the reaction diagram
18% of activity compared to succinyl-Ala-Leu-(cis)-Pro-Phe-4-nitroanilide
-
-
?
succinyl-Ala-Val-(cis)-Pro-Phe-p-nitroanilide
succinyl-Ala-Val-(trans)-Pro-Phe-p-nitroanilide
show the reaction diagram
-
76% of the activity with succinyl-Ala-Ala-(cis)-Pro-Phe-p-nitroanilide
-
-
?
Succinyl-Arg-Leu-(cis)-Pro-Phe 4-nitroanilide
Succinyl-Arg-Leu-(trans)-Pro-Phe 4-nitroanilide
show the reaction diagram
-
-
-
-
Succinyl-Leu-Leu-(cis)-Pro-Phe 4-nitroanilide
Succinyl-Leu-Leu-(trans)-Pro-Phe 4-nitroanilide
show the reaction diagram
-
-
-
-
Succinyl-Phe-Leu-(cis)-Pro-Phe 4-nitroanilide
Succinyl-Phe-Leu-(trans)-Pro-Phe 4-nitroanilide
show the reaction diagram
-
-
-
-
Succinyl-Ser-Leu-(cis)-Pro-Phe 4-nitroanilide
Succinyl-Ser-Leu-(trans)-Pro-Phe 4-nitroanilide
show the reaction diagram
-
-
-
-
Trp-Phe-Tyr-pSer-Pro-Arg-4-nitroanilide
?
show the reaction diagram
-
-
-
-
?
Trp-Phe-Tyr-Ser(PO3H2)-(cis)-Pro-Arg-4-nitroanilide
Trp-Phe-Tyr-Ser(PO3H2)-(trans)-Pro-Arg-4-nitroanilide
show the reaction diagram
-
-
-
-
?
VYKS-(cis)-PVVSGDTS-(cis)-PRHL
VYKS-(trans)-PVVSGDTS-(trans)-PRHL
show the reaction diagram
interconversion occurs at both P5 and P13
-
-
?
additional information
?
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
AGL24 protein
?
show the reaction diagram
-
cis/trans conformational change of phosphorylated Ser/Thr-Pro motif. The interaction between Pin1At and AGL24 mediates the AGL24 stability in the nucleus
-
-
?
amyloidbeta precursor protein
?
show the reaction diagram
-
interaction with Thr688
-
-
?
colicin M
?
show the reaction diagram
hepatitis C virus NS5A protein
?
show the reaction diagram
-
nonstructural 5A protein, NS5A, from the JFH1 hepatitis C virus strain. Mutations in this domain are linked to cyclosporin A resistance
-
-
?
interleukin-2 tyrosine kinase
?
show the reaction diagram
-
catalytic activity of interleukin-2 tyrosine kinase is inhibited by peptidylprolyl isomerase activity of cyclophilin A. Proline-dependent conformational switch within the interleukin-2 tyrosine kinase SH2 domain regulates substrate recognition and mediates regulatory interactions with the active site of cyclophilin A
-
?
peptidylproline (omega=180)
peptidylproline (omega=0)
show the reaction diagram
-
-
-
-
?
phosphorylated pro-apoptotic Bcl-2-associated X protein
?
show the reaction diagram
-
Pin1 prevents activation of Bax, prevents Bax cleavage by calpain, and prevents Bax translocation to mitochondria
-
-
?
PP2A phosphatase with cis-P190
PP2A phosphatase with trans-P190
show the reaction diagram
protein tau
?
show the reaction diagram
-
interaction with Thr231 of tau in Alzheimer's disease
-
-
?
RNA polymerase II
?
show the reaction diagram
serine/threonine protein kinase B
?
show the reaction diagram
-
-
-
-
?
SOC1 protein
?
show the reaction diagram
-
cis/trans conformational change of phosphorylated Ser/Thr-Pro motif
-
-
?
additional information
?
-
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(1,2-dimethyl-1H-indol-3-yl)(5'-fluoro-2',4-dihydroxy-1,1'-biphenyl-3-yl)methanone
-
-
(1R)-1,3-diphenyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-piperidinecarboxylate
-
-
(1R)-1,3-diphenylpropyl 1-(3,3-dimethyl-2-oxopentanoyl)piperidine-2-carboxylate
-
-
(1R)-1-cyclohexyl-3-phenylpropyl 1-(3,3-dimethyl-2-oxopentanoyl)piperidine-2-carboxylate
-
-
(1R)-1-naphthalen-2-yl-3-phenylpropyl 1-(3,3-dimethyl-2-oxopentanoyl)piperidine-2-carboxylate
-
-
(1R)-1-phenyl-3-(3,4,5-trimethoxyphenyl)propyl 1-(3,3-dimethyl-2-oxopentanoyl)piperidine-2-carboxylate
-
-
(1R)-1-[3-(diethenylcarbamoyl)phenyl]-3-phenylpropyl 1-(3,3-dimethyl-2-oxopentanoyl)piperidine-2-carboxylate
-
inhibition of FKBP12 cis-trans peptidylprolyl isomerase activity, but no activity in splenocyte mitogenesis assay for immunosuppression
(1R)-3-(1,3-benzodioxol-5-yl)-1-phenylpropyl 1-(3,3-dimethyl-2-oxopentanoyl)piperidine-2-carboxylate
-
-
(1R)-3-(3,4-dimethoxyphenyl)-1-phenylpropyl 1-(3,3-dimethyl-2-oxopentanoyl)piperidine-2-carboxylate
-
-
(1R)-3-cyclohexyl-1-phenylpropyl 1-(3,3-dimethyl-2-oxopentanoyl)piperidine-2-carboxylate
-
-
(1R)-3-cyclohexyl-1-phenylpropyl 1-[cyclohexyl(oxo)acetyl]piperidine-2-carboxylate
-
-
(1R)-3-phenyl-1-[3-(phenylcarbonyl)phenyl]propyl 1-(3,3-dimethyl-2-oxopentanoyl)piperidine-2-carboxylate
-
inhibition of FKBP12 cis-trans peptidylprolyl isomerase activity, but no activity in splenocyte mitogenesis assay for immunosuppression
(1R,5S)-1-(phenylsulfonyl)bicyclo[3.3.1]nonan-3-one
-
-
(1R,5S)-1-(phenylthio)bicyclo[3.3.1]nonan-3-one
-
-
(1S)-1,3-diphenylpropyl 1-(benzylsulfonyl)piperidine-2-carboxylate
-
-
(1S)-1-cyclohexyl-3-phenylpropyl (2R)-1-(3,3-dimethyl-2-oxopentanoyl)piperidine-2-carboxylate
-
-
(1S)-1-phenyl-3-(3,4,5-trimethoxyphenyl)propyl 1-(3,3-dimethylbutanoyl)piperidine-2-carboxylate
-
-
(2,5-dimethyl-1-benzofuran-3-yl)(2-hydroxy-5-iodophenyl)methanone
-
-
(2,5-dimethyl-1-benzofuran-3-yl)(2-hydroxy-5-methylphenyl)methanone
-
-
(2,5-dimethyl-1-benzofuran-3-yl)(3',4,5'-trihydroxy-1,1'-biphenyl-3-yl)methanone
-
-
(2,5-dimethyl-1-benzofuran-3-yl)(5'-fluoro-2',4-dihydroxy-1,1'-biphenyl-3-yl)methanone
-
-
(2,5-dimethyl-1-benzofuran-3-yl)[2-hydroxy-5-(trifluoromethyl)phenyl]methanone
-
-
(2,5-dimethyl-1-benzofuran-3-yl)[4-hydroxy-4'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]methanone
-
-
(2-butyl-1-benzothiophen-3-yl)(5'-fluoro-2',4-dihydroxy-1,1'-biphenyl-3-yl)methanone
-
-
(24aS)-17,17-dimethylhexadecahydropyrido[2,1-c][1,9,4]dioxazacyclohenicosine-1,14,18,19(3H,21)-tetrone
-
-
(3S,26aR)-19,19-dimethyl-3-(2-phenylethyl)-12,13,14,15,18,19,24,25,26,26a-decahydro-3H,10H-4,8-(metheno)pyrido[2,1-c][1,9,17,4]trioxazacyclotricosine-1,16,20,21(11H,23H)-tetrone
-
-
(5'-fluoro-2',4-dihydroxy-1,1'-biphenyl-3-yl)(2-methyl-1-benzofuran-3-yl)methanone
-
-
(5'-fluoro-2',4-dihydroxy-1,1'-biphenyl-3-yl)(2-methyl-1-benzothiophen-3-yl)methanone
-
-
(5'-fluoro-2',4-dihydroxybiphenyl-3-yl)(2-methyl-1-benzofuran-3-yl)methanethione
-
-
(5'-fluoro-2',4-dihydroxybiphenyl-3-yl)(2-methyl-1-benzothiophen-3-yl)methanethione
-
-
(5'-fluoro-2',4-dimethoxybiphenyl-3-yl)(2-methyl-1-benzofuran-3-yl)methanethione
-
-
(5-bromo-2-hydroxyphenyl)(2,5-dimethyl-1-benzofuran-3-yl)methanone
-
-
(6,8aR)-6-N,N-monophenylimino-8a-carboxyindolizidin-5-one methyl ester
-
dissociation constant: above 0.2 mM
(6R,8a,R)-6-(2-methylnaphthyl)-N-tert-butoxycarbonyl-6-amino-8a-carboxyindolizidin-5-one methyl ester
-
dissociation constant: 0.017 mM
(6R,8aR)-6-(2-methylnaphthyl)-N-acetyl-6-amino-8a-carboxyindolizidin-5-one methyl ester
-
dissociation constant: 0.0015 mM
(6R,8aR)-6-(2-methylnaphthyl)-N-benzyloxycarbonyl-6-amino-8a-carboxyindolizidin-5-one methyl ester
-
dissociation constant: 0.047 mM
(6R,8aR)-6-(2-methylnaphthyl)-N-tert-butoxycarbonyl-6-amino-8a-indolizidine methyl ester
-
dissociation constant: 0.077 mM
(6R,8aR)-6-benzyl-6-N-tert-butoxycarbonylamino-8a-carboxyindolizidin-5-one methyl ester
-
dissociation constant: 0.14 mM
(6R,8aR)-6-benzyl-N-benzyloxycarbonyl-6-amino-8a-carboxyindolizidin-5-one methyl ester
-
dissociation constant: 0.124 mM
(6R,8aR)-6-N-tert-butoxycarbonylamino-8a-carboxyindolizidine methyl ester
-
dissociation constant: 0.2 mM
(6S,8aR)-6-N-tert-butoxycarbonylamino-8a-carboxyindolizidine methyl ester
-
dissociation constant: above 0.2 mM
(E)-2-(2-hydroxy-2-isobutylethy 1idene)-1-meth ylcyclopentane-(L)-tyrosylcarboxamide
-
-
1-(1H-imidazol-2-ylthio)bicyclo[3.3.1]nonan-3-one
-
-
1-(2-phenylethyl)-4-pyridin-3-ylbutyl (2R)-1-[difluoro(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate
-
-
1-(3-hydroxyphenoxy)bicyclo[3.3.1]nonan-3-one
-
-
1-(phenylthio)bicyclo[3.3.1]nonan-3-one
-
-
1-(pyridin-3-ylthio)bicyclo[3.3.1]nonan-3-one
-
-
1-(pyridin-4-ylthio)bicyclo[3.3.1]nonan-3-one
-
-
1-benzyl-2-pyridin-3-ylethyl 1-[difluoro(3,4,5-trimethoxyphenyl)acetyl]-D-prolinate
-
-
1-benzyl-3-phenylpropyl 1-(3,3-dimethyl-2-oxopentanoyl)piperidine-2-carboxylate
-
-
1-phenyl-3-pyridin-3-ylpropyl (2R)-1-[difluoro(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate
-
-
1-[(1R,10S)-3,8-dioxa-14-azabicyclo[8.3.1]tetradec-14-yl]-3,3-dimethyl-1-oxopentan-2-one
-
15,15-dimethyltetradecahydropyrido[2,1-c][1,9,4]dioxazacyclononadecine-1,12,16,17(3H,19H)-tetrone
-
-
2,7-dimethylbenzo[lmn][3,8]phenanthroline-1,3,6,8(2H,7H)-tetrone
-
IC50: 0.002 mM
2-(4-((2R)-2-[(1R,3R,5R)-3,5-dimethyl-2-oxocyclohexyl]-2-hydroxyethyl)-2,6-dioxopiperidin-1-yl)acetamide
-
competitive inhibition. Evaluation of cytotoxicity against cell lines L-929 fibroblasts and K-562 leukemic cells
2-oxo-2-[(1R,10S)-5-phenoxy-3,8-dioxa-14-azabicyclo[8.3.1]tetradec-14-yl]-1-(3,4,5-trimethoxyphenyl)ethanone
-
2-[(1R,10S)-3,8-dioxa-14-azabicyclo[8.3.1]tetradec-14-yl]-2-oxo-1-(3,4,5-trimethoxyphenyl)ethanone
-
3,5-dichloro-N-(3-[(2-naphthylacetyl)amino]phenyl)benzamide
-
-
3,5-dichloro-N-[3-([[(2,4-dibromophenyl)amino]carbonyl]amino)phenyl]benzamide
-
-
3,5-dichloro-N-[3-([[(3,5-dichlorophenyl)amino]carbonyl]amino)phenyl]benzamide
-
-
3,5-dichloro-N-[3-[(3,3-diphenylpropanoyl)amino]phenyl]benzamide
-
-
3,5-dichloro-N-[3-[([[4-(trifluoromethyl)phenyl]amino]carbonyl)amino]phenyl]benzamide
-
-
3-(3,4,5-trimethoxyphenyl)propyl (2R)-1-(3,3-dimethyl-2-oxopentanoyl)piperidine-2-carboxylate
-
-
3-(3,4,5-trimethoxyphenyl)propyl 1-(3,3-dimethyl-2-oxopentanoyl)piperidine-2-carboxylate
-
-
3-(3,4,5-trimethoxyphenyl)propyl 1-(benzylsulfonyl)piperidine-2-carboxylate
-
-
3-phenyl-1-(2-pyridin-3-ylethyl)propyl 1-[difluoro(3,4,5-trimethoxyphenyl)acetyl]-D-prolinate
-
-
3-phenylpropyl 1-(2-hydroxy-3,3-dimethylpentanoyl)piperidine-2-carboxylate
-
-
4-phenyl-1-(2-pyridin-3-ylethyl)butyl (2R)-1-[difluoro(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate
-
-
4-phenyl-1-(3-pyridin-3-ylpropyl)butyl (2R)-1-[difluoro(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate
-
-
4-[2-(3,5-dimethyl-2-oxocyclohexyl)-2-hydroxyethyl]-2,6-piperidinedione
-
competitive inhibition. Evaluation of cytotoxicity against cell lines L-929 fibroblasts and K-562 leukemic cells
4-[2-(3,5-dimethyl-2-oxocyclohexyl)-2-hydroxyethyl]-2,6-piperidinedione-1-(4-ethyl butanoate)
-
competitive inhibition. Evaluation of cytotoxicity against cell lines L-929 fibroblasts and K-562 leukemic cells
4-[2-(3,5-dimethyl-2-oxocyclohexyl)-2-hydroxyethyl]-2,6-piperidinedione-1-(ethyl ethanoate)
-
competitive inhibition. Evaluation of cytotoxicity against cell lines L-929 fibroblasts and K-562 leukemic cells. Compound is able to significantly speed nerve regeneration in a rat sciatic nerve neurotomy model
5-hydroxy-1,4-naphthoquinone
5-methoxy-1',3'dihydro-3H-spiro[1-benzofuran-2,2'-indene]-3-one
-
-
5-methoxy-2',3'-dihydro-3H-spiro[1-benzofuran-2,1'-indene]-3-one
-
-
5-methoxy-3H-spiro[1-benzofuran-2,1'-cyclopent[3]en]-3-one
-
-
Ac-Ala-GlyPSI(PO2Et-N)Pro-Phe-4-nitroanilide
-
transition-state analogue of peptidylprolyl isomerase activity of cyclophilin Cyp-18, Kd value 0.127 mM
Ac-beta-(3-benzothienyl)Ala-Thr(PO3H2)-piperidine-2-carboxylic acid-beta-(2-naphthyl)Ala-Gln-NH2
-
-
Ac-Lys(Nepsilon-biotinoyl)-Ala-Ala-(t-butyl)Phe-Thr(PO3H2)-(methyl)Ala-beta-(2-naphthyl)Ala-Gln-NH2
-
-
Ac-Lys(Nepsilon-biotinoyl)-Ala-Ala-(t-butyl)Phe-Thr(PO3H2)-Yaa-Zaa-Gln-NH2
-
-
Ac-Lys(Nepsilon-biotinoyl)-Ala-Ala-beta-(2-thienyl)Ala-Thr(PO3H2)-(methyl)Ala-beta-(2-naphthyl)Ala-Gln-NH2
-
-
Ac-Lys(Nepsilon-biotinoyl)-Ala-Ala-beta-(3-benzothienyl)Ala-D-Thr(PO3H2)-piperidine-2-carboxylic acid-beta-(2-naphthyl)Ala-Gln-NH2
-
-
Ac-Lys(Nepsilon-biotinoyl)-Ala-Ala-beta-(3-benzothienyl)Ala-Thr(PO3H2)-piperidine-2-carboxylic acid-beta-(2-naphthyl)Ala-Gln-NH2
-
-
Ac-Lys(Nepsilon-biotinoyl)-Ala-Ala-beta-cyclohexylAla-Thr(PO3H2)-(methyl)Ala-beta-(2-naphthyl)Ala-Gln-NH2
-
-
Ac-Lys(Nepsilon-biotinoyl)-Ala-Ala-Phe-D-Thr(PO3H2)-piperidine-2-carboxylic acid-beta-(2-naphthyl)Ala-Gln-NH2
-
-
Ac-Phe-D-Thr(PO3H2)-piperidine-2-carboxylic acid-beta-(2-naphthyl)Ala-Gln-NH2
-
-
Ac-Phe-Thr(PO3H2)-piperidine-2-carboxylic acid-beta-(2-naphthyl)Ala-Gln-NH2
-
-
acetyl-Ala-Ala-D-Ser(PO3H2)-Pro-Leu-NH-4-nitroanilide
-
IC50: 0.001 mM
acetyl-Ala-Ala-D-Ser-Pro-Leu-NH-4-nitroanilide
-
IC50: 0.085 mM
acetyl-Ala-Pro-Phe-4-(trimethylammonium)anilide
-
IC50: 7 mM
acetyl-Ala-Pro-Phe-4-nitroanilide
-
IC50: 0.77 mM
Ala-Pro
alpha-lactalbumin
-
unfolded
-
benzyl (2S)-1-[[(1S,2R,5R)-1-hydroxy-5-[(1R)-1-methoxy-3-methylbut-2-en-1-yl]-2-methylcyclohexyl](oxo)acetyl]piperidine-2-carboxylate
-
-
benzyl (2S)-1-[[(1S,2R,5R)-1-hydroxy-5-[(1S)-1-methoxy-3-methylbutyl]-2-methylcyclohexyl](oxo)acetyl]piperidine-2-carboxylate
-
-
benzyl (2S)-1-[[(1S,2R,5R)-1-hydroxy-5-[(1S)-1-methoxyethyl]-2-methylcyclohexyl](oxo)acetyl]piperidine-2-carboxylate
-
-
Cu2+
-
-
cyclic CRYPEVEIC
-
the cyclic peptide is specific for the active site of the PPIase domain
cyclo(Arg-Arg-Arg-D-pThr-Pip-Nal-Arg-Arg-Gln)
-
-
cyclo(Arg-Arg-Arg-D-Thr-Pip-Nal-Arg-Arg-Gln)
-
-
cyclo(D-Ala-Gln-Glu-Mpa-Mal-Ile-Gln)
-
-
cyclo(D-Ala-Gly-D-pThr-Pip-Nal-Orn-Gln)
-
-
cyclo(D-Ala-Ile-D-pSer-Pro-Nal-Orn-Gln)
-
-
cyclo(D-Ala-Sar-D-pThr-Pip-Nal-Tyr-Gln)
-
-
cyclo(D-Ala-Sar-D-pThr-Pip-Nal-Tyr-Gln)-Lys-SH
-
-
cyclo(D-Arg-D-Arg-D-pThr-Pip-Nal-Arg-D-Arg-D-Arg-D-Arg-Gln)
-
-
cyclo(D-Arg-D-Arg-D-pThr-Pip-Nal-Arg-Gln)
-
-
cyclo(D-Arg-D-Arg-D-Thr-Pip-Nal-Arg-D-Arg-D-Arg-D-Arg-Gln)
-
-
cyclo(D-Arg-D-Arg-D-Thr-Pip-Nal-Arg-Gln)
-
-
cycloheximide
-
-
cyclolinopeptide A
-
interaction with several synthetic analogues cyclolinopeptide A
cyclosporin A
D-Ser(PO3H2)-Pro
-
1 mM, 20% inhibition
diethyl 1,3,8,10-tetrahydro-1,3,8,10-tetraoxoanthra[2,1,9-def:6,5,10-d'e'f']diisoquinoline-2,9-diacetate
-
IC50: 0.0015 mM
diethyl 2,2'-(1,3,6,8-tetraoxo-1,3,6,8-tetrahydrobenzo[lmn][3,8]phenanthroline-2,7-diyl)diacetate
diethyl 2,2'-(1,3,8,10-tetraoxo-1,3,8,10-tetrahydroisoquinolino[4',5',6':6,5,10]anthra[2,1,9-def]isoquinoline-2,9-diyl)diacetate
diethyl-1,3,6,8-tetrahydro-1,3,6,8-tetraoxobenzo[lmn][3,8]phenanthroline 2,7-diacetate
-
IC50: 0.0015 mM, inhibitor with the least non-specific toxicity
dipentamethylene thiuram monosulfide
ethyl (2S)-1-(4,4-dimethyl-2-oxohexanoyl)piperidine-2-carboxylate
-
-
ethyl (2S)-1-[(2-methoxycyclohexyl)(oxo)acetyl]piperidine-2-carboxylate
-
-
ethyl (2S)-1-[cyclohexyl(oxo)acetyl]piperidine-2-carboxylate
-
-
ethyl 1-(4,4-dimethyl-2-oxopentanoyl)piperidine-2-carboxylate
-
-
ethyl 1-(4-methyl-2-oxopentanethioyl)piperidine-2-carboxylate
-
-
ethyl 1-(4-methyl-2-oxopentanoyl)piperidine-2-carboxylate
-
-
ethyl 1-(5-ethoxy-4,4-dimethyl-2-oxopentanoyl)piperidine-2-carboxylate
-
-
ethyl 1-[(1-methoxycyclohexyl)(oxo)acetyl]pyrrolidine-2-carboxylate
-
-
ethyl 1-[(3-methoxytetrahydro-2H-pyran-2-yl)(oxo)acetyl]piperidine-2-carboxylate
-
-
GPI-1046
Hg2+
-
-
juglone
lactalbumin
-
reduced and carboxymethylated, strong inhibition by the permanently unfolded protein
-
linear CRYPEVEIC
-
-
methyl N-([(1R,2E)-2-[(2S)-2-hydroxy-4-methylpentylidene]-1-methylcyclopentyl]carbonyl)-L-tyrosinate
-
-
N,N''-(4,6-dibromo-1,3-phenylene)bis[3-(4-iodophenyl)urea]
-
-
N,N'-1,3-phenylenebis(3,5-dichlorobenzamide)
-
-
NEM
-
cytosolic enzyme form
non-folding vartiant of ribonuclease T1
-
that lacks Pro39
-
PCMB
-
-
Phe-Ser(PO3H2)-PSI[CS-N]-Pro-Phe-NH-4-nitroanilide
-
IC50: 0.004 mM
Phe-Ser-PSI[CS-N]-Pro-Phe-NH-4-nitroanilide
-
IC50: 0.097 mM
Phenylglyoxal
-
cytosolic enzyme form
QAEGPK
peptide corresponding to peptide QAEGP487KR at the N-terminus of the enzyme's isomerase domain. Peptide binds to the active site, but the enzyme does not catalyze its isomerization
Rapamycin
RNase T1
-
reduced and carboxymethylated form of the P39A variant, strong inhibition by the permanently unfolded protein
-
SDS
-
-
Ser(PO3H2)-Pro
-
; IC50: 2.0 mM
Ser-Pro
-
-
Ser-PSI[CS-N]-Pro
-
-
Suc-Ala-Ala-Pro-Phe-4-nitroanilide
-
transition-state analogue of peptidylprolyl isomerase activity of cyclophilin Cyp-18, Kd value 0.138 mM
Suc-Ala-GlyPSI(PO2Et-N)Pro-Phe-4-nitroanilide
-
transition-state analogue of peptidylprolyl isomerase activity of cyclophilin Cyp-18, Kd value 0.02 mM. Selectively inhibits Cyp-18, but not enzyme isoform FKBP12
succinyl-Ala-Ala-Pro-NH2
-
IC50: 14 mM
succinyl-Ala-Ala-Pro-Phe-4-carboxymethylanilide
-
IC50: 4.4 mM
succinyl-Ala-Ala-Pro-Phe-4-nitroanilide
-
IC50: 0.54 mM
succinyl-Ala-Pro-Phe-4-aminoanilide
-
IC50: 5.8 mM
succinyl-Ala-Pro-Phe-4-carboxmethylanilide
-
IC50: 0.7 mM
succinyl-Ala-Pro-Phe-4-nitroanilide
-
IC50: 0.17 mM
succinyl-Pro-Phe-4-nitroanilide
-
IC50: 1.09 mM
[(1S,2R,3S,6R,7aR)-2-(benzylcarbamoyl)-6-methoxy-3-naphthalen-2-ylhexahydro-1H-pyrrolizin-1-yl]methyl dihydrogen phosphate
-
-
[(1S,2R,3S,6S,7aR)-2-(benzylcarbamoyl)-6-fluoro-3-naphthalen-2-ylhexahydro-1H-pyrrolizin-1-yl]methyl dihydrogen phosphate
-
-
[(1S,2R,3S,7aR)-2-(benzylcarbamoyl)-3-(pentafluorophenyl)hexahydro-1H-pyrrolizin-1-yl]methyl dihydrogen phosphate
-
-
[(1S,2R,3S,7aR)-2-(benzylcarbamoyl)-3-naphthalen-2-ylhexahydro-1H-pyrrolizin-1-yl]methyl dihydrogen phosphate
-
-
[(1S,2R,3S,7aR)-2-(benzylcarbamoyl)-3-phenylhexahydro-1H-pyrrolizin-1-yl]methyl dihydrogen phosphate
-
-
[(1S,2R,3S,7aR)-2-[(1,3-benzodioxol-5-ylmethyl)carbamoyl]-3-naphthalen-2-ylhexahydro-1H-pyrrolizin-1-yl]methyl dihydrogen phosphate
-
-
[3-[(5'-fluoro-2',4-dihydroxy-1,1'-biphenyl-3-yl)carbonyl]-2-methyl-1-benzofuran-5-yl]acetonitrile
-
-
additional information